Pricing, Distribution, and Reimbursement

APONVIE is Priced to Support Broad Access, With Convenient Packaging and Distribution

WAC: $58.00 per vial

340B: ≥23.1% discount

Vial contains single 32-mg dose. Packaged in cartons of 10 vials.

Download the APONVIE Ordering and Pricing Information and the APONVIE Distribution Guide for more details.

Note: Pricing as of March 3, 2023. 340B prices update quarterly. Confirm current pricing with your Heron representative.

WAC: wholesale acquisition cost.

GPO: group purchasing organization.

FSS: Federal Supply Schedule.

APONVIE Is Separately Reimbursed by Medicare in HOPDs and ASCsa


Effective April 1, 2023,
use C9145 when
billing for APONVIE

Medicare Reimbursement

During 3-year pass-through statusa:

ASP + 6% in HOPDs and ASCsb

APONVIE is the only product in its class separately reimbursed by Medicare in HOPDs and ASCsa

Generic PONV medications like oral aprepitant and other drugs without pass-through status are packaged across all settings of care.c

Commercial Reimbursement

  • Some commercial payers reimburse separately for APONVIE as a percentage of billed charges. However, most package APONVIE across all sites of care. Contact payers to verify coverage.
  • Commercial payers have been notified of commercial availability and the product-specific code

Download the APONVIE Reimbursement Guide for more details.

aCoverage under 3-year transitional pass-through status effective April 1, 2023.

bAPONVIE will be reimbursed at WAC + 3% until ASP is established.

cReimbursement comparisons do not imply safety or efficacy.

HOPD: hospital outpatient department.

ASC: ambulatory surgical center.

ASP: average sales price.

WAC: wholesale acquisition cost.


[+] Expand@!

Important Safety Information!


APONVIE is contraindicated in patients with a history of hypersensitivity to aprepitant or any component of the product, and in patients taking pimozide. Increased pimozide levels may cause serious or life-threatening reactions, such as QT prolongation.

Warnings and Precautions

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of aprepitant have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. Monitor patients during and after administration. If hypersensitivity reactions occur, administer appropriate medical therapy. Do not administer APONVIE in patients who experienced these symptoms with previous use of aprepitant.

Clinically Significant CYP3A4 Drug Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated. Use of APONVIE with strong CYP3A4 inhibitors (eg, ketoconazole) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to APONVIE. Use of APONVIE with strong CYP3A4 inducers (eg, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of APONVIE.

Decrease in INR with Concomitant Warfarin: Use of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period particularly at 7 to 10 days, following administration of APONVIE.

Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced for 28 days following administration of APONVIE. Advise patients to use effective alternative or back-up methods of non-hormonal contraception for 1 month following administration of APONVIE.

Use in Specific Populations

Avoid use of APONVIE in pregnant women as alcohol is an inactive ingredient in APONVIE. There is no safe level of alcohol exposure in pregnancy.

Adverse Reactions

Most common adverse reactions (incidence ≥3%) for APONVIE are constipation, fatigue, and headache and for oral aprepitant are constipation and hypotension.

Report side effects to Heron at 1-844-437-6611 or to the FDA at 1-800-FDA-1088 or


APONVIE is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.

Limitations of Use: APONVIE has not been studied for treatment of established nausea and vomiting.

Please see full Prescribing Information.

Full Prescribing Information

Connect with Heron!

How could you incorporate APONVIE as the foundation of your institution's PONV management strategy? Connect with us to find out.

Fields marked with an asterisk (*) are required.

I would like to*:

To report an adverse event or product complaint:

844-HERON11 (844-437-6611)

For general information:

844-HERON11 (844-437-6611)

Investors and Media:

For all other inquiries, please visit the Heron Therapeutics corporate website.

Go to Heron Website